Who Paid My Doc
Richard Ferro
Interventional Pain Medicine Lansing, MI Medical Doctor
NPI 1528008372 CMS profile 341444
3960 Patient Care Dr, Suite 117, Lansing, MI 48911
General payments
$30,751
Research payments
$174,840
Ownership & investment interest
$0
Research they led as principal investigator
$1,000
Through program year 2025, Richard Ferro of Lansing, MI is reported in the CMS Open Payments database as having received $30,751 across 317 general payments and $174,840 in research payments paid to them. Separately, studies naming them as principal investigator received $1,000 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 97th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
13 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $955 | 32 | |
| 2025 | Research | $6,665 | 5 | |
| 2024 | General | $557 | 33 | |
| 2024 | Research | $24,151 | 10 | |
| 2023 | General | $12,973 | 36 | |
| 2023 | Research | $34,489 | 9 | |
| 2022 | General | $2,297 | 40 | |
| 2022 | Research | $53,250 | 9 | |
| 2021 | General | $8,545 | 49 | |
| 2021 | Research | $30,163 | 8 | |
| 2020 | General | $2,742 | 41 | |
| 2020 | Research | $26,122 | 3 | |
| 2019 | General | $2,682 | 86 |
Beside peers
- Richard Ferro
- Interventional Pain Medicine median
- Middle half of Interventional Pain Medicine
- National median
In program year 2025, general payments to Richard Ferro were reported at $955. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.
Show as a table
| Year | Richard Ferro | Interventional Pain Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $2,682 | $684 | $216–$2,079 | $163 |
| 2020 | $2,742 | $382 | $122–$1,109 | $114 |
| 2021 | $8,545 | $552 | $167–$1,554 | $132 |
| 2022 | $2,297 | $605 | $187–$1,924 | $149 |
| 2023 | $12,973 | $671 | $195–$1,915 | $160 |
| 2024 | $557 | $684 | $206–$1,837 | $164 |
| 2025 | $955 | $657 | $184–$1,753 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 21 drugsPart D claims
2,271
Drug cost
$78,281
Branded share of claims
62.8%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | Brand | 1,147 | $26,186 | |
| Xtampza Er Oxycodone Myristate | Brand | 13 | $14,608 | |
| Movantik Naloxegol Oxalate | Brand | 25 | $13,095 | |
| Oxycontin Oxycodone Hcl | Brand | 12 | $6,895 | |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | Brand | 144 | $4,806 | |
| Morphine Sulfate | Generic | 36 | $1,496 | |
| Oxycodone Hcl | Generic | 83 | $1,394 | |
| Gabapentin | Generic | 94 | $1,337 | |
| Pregabalin | Generic | 44 | $1,255 | |
| Tramadol Hcl | Generic | 112 | $1,113 |
The 10 drugs with the highest cost, of 21 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,517 Part D prescribers listed as Anesthesiology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 42 billing codesPaid by Medicare
$159,021
Medicare patients
194
Services billed
1,144
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| Arthritis | 75% | |
| High blood pressure | 71% | |
| Depression | 40% | |
| Ischemic heart disease | 29% | |
| Diabetes | 28% | |
| COPD | 28% | |
| Chronic kidney disease | 22% | |
| Heart failure | 18% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
361 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Interventional Pain Medicine in Michigan
Ryan Pollina
Interventional Pain Medicine · Saint Clair Shores, MI
Ariel Majjhoo
Interventional Pain Medicine · Monroe, MI
Chad Brummett
Interventional Pain Medicine · Ann Arbor, MI
Anand Thakur
Interventional Pain Medicine · Clinton Township, MI
Evan Peskin
Interventional Pain Medicine · Flint, MI
John Chatas
Interventional Pain Medicine · Ann Arbor, MI
Related records
Interventional Pain Medicine in Michigan
Practitioners in the same specialty and state, ranked by reported value.
All Interventional Pain Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Michigan
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.